We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-5.11%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$549M
AUM Growth
+$38.2M
Cap. Flow
+$95.8M
Cap. Flow %
17.45%
Top 10 Hldgs %
48.43%
Holding
55
New
15
Increased
11
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$42.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.6M
3
ALKS icon
Alkermes
ALKS
+$13.6M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.1M
5
REPL icon
Replimune Group
REPL
+$12.5M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$20.9M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$12.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$9.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$9.31M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$6.65M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
1
UroGen Pharma
URGN
$1.86B
$36.7M 6.69%
+2,620,545
New +$42.1M
ALPN
2
DELISTED
Alpine Immune Sciences Inc
ALPN
$35.3M 6.42%
3,078,633
-285,055
-8% -$3.51M
PLRX icon
3
Pliant Therapeutics
PLRX
$64.4M
$30.4M 5.54%
1,755,184
+205,000
+13% +$3.55M
PCVX icon
4
Vaxcyte
PCVX
$7.81B
$27.1M 4.93%
531,211
-58,000
-10% -$2.86M
RARE icon
5
Ultragenyx Pharmaceutical
RARE
$2.45B
$25.9M 4.72%
727,426
+50,000
+7% +$1.98M
ALKS icon
6
Alkermes
ALKS
$8.22B
$24.5M 4.46%
875,044
+463,591
+113% +$13.6M
RAPT
7
DELISTED
RAPT Therapeutics
RAPT
$24.2M 4.41%
182,259
-885
-0.5% -$144K
ZURA icon
8
Zura Bio
ZURA
$516M
$21.7M 3.96%
3,295,000
– –
SRPT icon
9
Sarepta Therapeutics
SRPT
$1.57B
$20M 3.65%
165,200
+41,600
+34% +$4.7M
EOLS icon
10
Evolus
EOLS
$385M
$20M 3.64%
2,186,934
-247,114
-10% -$2.22M
PNT
11
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$19.4M 3.54%
2,909,960
-90,040
-3% -$748K
CYTK icon
12
Cytokinetics
CYTK
$10.5B
$17.7M 3.22%
600,000
– –
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.06B
$17.1M 3.11%
500,001
-29,999
-6% -$1.12M
ANAB icon
14
AnaptysBio
ANAB
$1.58B
$16.1M 2.93%
894,333
– –
IMCR icon
15
Immunocore
IMCR
$1.72B
$15.1M 2.75%
290,917
-6,165
-2% -$365K
JBIO
16
Jade Biosciences
JBIO
$1.2B
$14.8M 2.7%
31,178
+4,545
+17% +$2.46M
ITCI
17
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.7M 2.13%
+225,000
New +$13.1M
ACRS icon
18
Aclaris Therapeutics
ACRS
$726M
$11.6M 2.11%
1,691,768
-249,813
-13% -$2.13M
SRPT icon
19
PUT
Sarepta Therapeutics
SRPT
$1.57B
$11.5M 2.1%
+95,000
New +$10.7M
PTCT icon
20
PTC Therapeutics
PTCT
$5.64B
$11.2M 2.04%
+500,000
New +$18.6M
REPL icon
21
Replimune Group
REPL
$941M
$10.9M 1.99%
+638,495
New +$12.5M
OPTN
22
DELISTED
OptiNose
OPTN
$10.9M 1.98%
589,329
– –
FOLD
23
DELISTED
Amicus Therapeutics
FOLD
$10.4M 1.9%
857,000
+155,608
+22% +$2.01M
ACLX
24
DELISTED
Arcellx
ACLX
$10.3M 1.88%
287,500
+250,000
+667% +$8.62M
KRTX
25
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$10.2M 1.86%
+60,500
New +$11.4M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Great Point Partners held 55 positions worth $549M, up 7.5% from $511M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Great Point Partners deployed $95.8M of net new capital in Q3 2023, opening 15 new positions and adding to 11 existing holdings. Its largest new stake was UroGen Pharma: 2,620,545 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Gracell Biotechnologies Inc. American Depositary Shares, an estimated $6.17M trimmed.

  • Great Point Partners's largest Q3 2023 buy was UroGen Pharma: 2,620,545 shares worth $36.7M.
  • Great Point Partners added most to Alkermes in Q3 2023, an estimated $13.6M increase.
  • Great Point Partners's biggest Q3 2023 reduction was Gracell Biotechnologies Inc. American Depositary Shares, cutting an estimated $6.17M.
  • Great Point Partners fully exited Amylyx Pharmaceuticals in Q3 2023, selling an estimated $20.9M.
  • Great Point Partners's ten largest holdings make up 48% of its $549M portfolio in Q3 2023.
  • Great Point Partners opened 15 new positions and closed 13 in Q3 2023.
  • Great Point Partners's portfolio value rose 7.5% quarter-over-quarter to $549M.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.